Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis
Public ClinicalTrials.gov record NCT02301624. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Open-label Extension Trial of ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate the safety and efficacy of eculizumab in the treatment of refractory generalized myasthenia gravis (gMG) as an extension study for the participants who previously completed Study ECU-MG-301(NCT01997229).
Study identification
- NCT ID
- NCT02301624
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 117 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 12, 2014 (Actual)
- Primary completion
- Jan 15, 2019 (Actual)
- Completion
- Jan 15, 2019 (Actual)
- Last update posted
- Feb 5, 2020
2014 – 2019
United States locations
- U.S. sites
- 26
- U.S. states
- 17
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35233 | — |
| Not listed | Los Angeles | California | 90033 | — |
| Not listed | Orange | California | 92868 | — |
| Not listed | Palo Alto | California | 94304 | — |
| Not listed | San Francisco | California | 94115 | — |
| Not listed | New Haven | Connecticut | 06519 | — |
| Not listed | Jacksonville | Florida | 32209 | — |
| Not listed | Miami | Florida | 33136 | — |
| Not listed | Tampa | Florida | 33612 | — |
| Not listed | Springfield | Illinois | 62702 | — |
| Not listed | Indianapolis | Indiana | 46202 | — |
| Not listed | Iowa City | Iowa | 52242 | — |
| Not listed | Kansas City | Kansas | 66160 | — |
| Not listed | Baltimore | Maryland | 21201-1595 | — |
| Not listed | Baltimore | Maryland | 21287-0876 | — |
| Not listed | Boston | Massachusetts | 02115 | — |
| Not listed | Burlington | Massachusetts | 01805 | — |
| Not listed | Las Vegas | Nevada | 89145 | — |
| Not listed | Chapel Hill | North Carolina | 27599 | — |
| Not listed | Charlotte | North Carolina | 28207 | — |
| Not listed | Durham | North Carolina | 27710 | — |
| Not listed | Columbus | Ohio | 43210 | — |
| Not listed | Portland | Oregon | 97239 | — |
| Not listed | San Antonio | Texas | 78229 | — |
| Not listed | Burlington | Vermont | 05401 | — |
| Not listed | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02301624, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 5, 2020 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02301624 live on ClinicalTrials.gov.